Phylogica IPO closes oversubscribed
Thursday, 24 March, 2005
Perth-based functional proteomics company Phylogica has closed its IPO after raising $5 million through the sale of 25 million shares at $0.20.
Although the IPO was heavily oversubscribed, no oversubscriptions were accepted.
Major investors in the float include listed investment group Biotech Capital (ASX:BTC) and the Australian Heritage Group. Azure Capital managed the IPO.
The company was spun out of the Telethon Institute for Child Health Research to commercialise technology developed by researchers at the institute and their collaborators at Fox Chase Cancer Center in the US.
The company is expected to float on the ASX at 10:30am on March 30, 2005, using the code PYC.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
